Narcolepsy Therapeutics Market – By Disease Type (Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy, Secondary Narcolepsy), Treatment Type (Central Nervous System Stimulants, Sodium Oxybate), Distribution Channel & Forecast, 2024 - 2032

Narcolepsy Therapeutics Market Size

Narcolepsy Therapeutics Market was valued at around USD 3.6 billion in 2023 and is estimated to grow at 8.2% CAGR from 2024 to 2032. The increasing prevalence of narcolepsy is a major factor driving the growth of the market. Narcolepsy, a chronic sleep disorder characterized by excessive daytime sleepiness and sudden muscle weakness (cataplexy), affects approximately 1 in 2,000 individuals in the U.S.
 

Narcolepsy therapeutics refer to the treatments and medications used to manage narcolepsy, a chronic sleep disorder characterized by excessive daytime sleepiness, sudden loss of muscle tone (cataplexy), sleep paralysis, and hallucinations. The goal of these therapies is to alleviate the symptoms, improve wakefulness, and enhance the quality of life for individuals with narcolepsy.
 

Narcolepsy Therapeutics Market Trends

Technological advancements in narcolepsy therapeutics are significantly driving market growth, particularly through the development of novel drugs and innovative delivery methods.
 

• Recent advancements include the emergence of orexin receptor agonists, targeting disruptions in orexin signaling crucial to narcolepsy. These drugs offer new hope for patients unresponsive to conventional therapies by regulating the sleep-wake cycle.
   
• Next-generation pharmacotherapies leverage neuropharmacological progress to target specific neurotransmitters involved in sleep regulation.
   
• For example, drugs such as Wakix (pitolisant) from Bioprojet Pharma and Lumryz (sodium oxybate) from Jazz Pharmaceuticals show promise in managing narcolepsy symptoms.
   
• Ongoing development, such as AXS-12 from Axsome Therapeutics, Inc., currently in phase-3 clinical trials, underscores continued efforts to enhance therapeutic options for cataplexy and excessive daytime sleepiness in narcolepsy.
   
• These advancements ensure more consistent release of active ingredients, enhancing treatment effectiveness and improving convenience for patients managing the condition.

Narcolepsy Therapeutics Market Analysis

Based on disease type, the market is categorized into narcolepsy with cataplexy (type 1), narcolepsy without cataplexy (type 2), and secondary narcolepsy. The narcolepsy with cataplexy (type 1) segment dominated the market, with a revenue share of around 55.3% in 2023.
 

• Narcolepsy type 1 is more readily diagnosed than narcolepsy type 2 or secondary narcolepsy due to the distinctive symptom of cataplexy, which is a sudden loss of muscle tone often triggered by strong emotions. This clear diagnostic criterion makes it easier to identify and diagnose, leading to a higher number of patients being treated for this type?.
   
• Additionally, pharmaceutical companies and researchers often focus more on narcolepsy type 1 because the presence of cataplexy provides a clear and measurable endpoint for clinical trials. This focus has resulted in more therapeutic options being developed and approved for narcolepsy type 1.
   

Based on treatment type, the narcolepsy therapeutics market is categorized into central nervous system stimulants, sodium oxybate, selective serotonin reuptake inhibitor, tricyclic antidepressants, and histamine H3 receptor antagonists. The central nervous system stimulants segment is anticipated to witness highest growth with USD 2.7 billion during the forecast period.
 

• CNS stimulants are highly effective in managing excessive daytime sleepiness (EDS), which is one of the primary symptoms of narcolepsy. Their ability to promote wakefulness makes them a cornerstone and increases their demand for narcolepsy treatment.
   
• Additionally, many CNS stimulants are available in generic forms, making them more affordable and accessible to a broader patient population. This increases their usage and segmental growth.

Based on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and other pharmacies. The retail pharmacies segment dominated the market, with a revenue share of around 48.6% in 2023.
 

• Retail pharmacies are widespread and easily accessible to the majority of the population. Patients can conveniently pick up their sleep medications close to their homes, which encourages regular adherence to prescribed treatments.
   
• Additionally, retail pharmacies offer over-the-counter products and supplements that may be recommended as part of a comprehensive narcolepsy management plan. Hence contributes to segmental growth.     

North America narcolepsy therapeutics market accounted for USD 1.6 billion revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• There has been a significant increase in awareness about narcolepsy among both the public and healthcare professionals in the region. Awareness campaigns and educational initiatives have helped in recognizing the symptoms early.
   
• For instance, “World Narcolepsy Day," which takes place annually on September 22nd. This global event, initiated by the non-profit organization Wake Up Narcolepsy in collaboration with other patient advocacy groups, raises the awareness about narcolepsy through various activities and initiatives in the region.
   

U.S. market holds a dominant position with the market share of 92% in 2023.  
 

• Modern lifestyles with irregular sleep patterns, high stress levels, and increased screen time contribute to sleep disorders, including narcolepsy.
   
• Additionally, higher incidence of conditions such as obesity and depression, which are associated with sleep disorders, also contribute to the increased prevalence of narcolepsy in the country.
   

Germany narcolepsy therapeutics industry is expected to grow significantly during the forecast period.
 

• Advances in sleep study technology and diagnostic criteria have improved the accuracy and speed of diagnosing narcolepsy, leading to an increase in diagnosed cases in the country.
   
• Additionally, Germany has a robust healthcare infrastructure, with access to advanced diagnostic facilities and specialized sleep centers, which facilitates the diagnosis and treatment of narcolepsy and drives the market growth.
   

China market is anticipated to witness a high growth rate from 2024-2032, due to several factors.
 

• The Chinese government has been investing heavily in expanding and improving healthcare services, including specialized sleep clinics and diagnostic facilities.
   
• Additionally, domestic pharmaceutical companies are increasingly involved in the research and development of narcolepsy treatments, enhancing local availability and demand in the country.
   

Narcolepsy Therapeutics Market Share

The narcolepsy therapeutics industry is competitive in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel therapeutics with improved efficiency and cost-effectiveness are key market strategies for narcolepsy medicines manufacturers, driving competition and innovation in the industry. This emphasis on innovation aims to address evolving clinical needs and enhance patient outcomes, positioning companies to gain market share and meet the growing demand for novel narcolepsy therapeutics.
 

Narcolepsy Therapeutics Market Companies

Some of the eminent market participants operating in the industry include:

• Avadel Pharmaceuticals
• Axsome Therapeutics Inc.
• Harmony Biosciences
• Jazz Pharmaceuticals PLC
• Mylan N.V.
• Novartis AG
• Rhodes Pharmaceuticals L.P.
• Shionogi Inc.
• Takeda Pharmaceutical Company
• Teva Pharmaceuticals Industries Ltd
• XWPharma Ltd.
   

Narcolepsy Therapeutics Industry News:

• In March 2024, Axsome Therapeutics announced that AXS-12 achieved the primary endpoint in the SYMPHONY Phase 3 trial in narcolepsy. The commercialization of AXS-12 is expected to generate significant revenue for Axsome Therapeutics, contributing to the company's growth and profitability.
   
• In May 2023, Avadel Pharmaceuticals announced Final FDA Approval of LUMRYZ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy. This approval enhanced the company’s narcolepsy portfolio and its positioning in the narcolepsy market.
   

Narcolepsy therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments:

Click here to Buy Section of this Report

                             

Market, By Disease Type

• Narcolepsy with cataplexy (type 1)
• Narcolepsy without cataplexy (type 2)
• Secondary narcolepsy

Market, By Treatment Type

• Central nervous system stimulants
• Sodium oxybate
• Selective serotonin reuptake inhibitor
• Tricyclic antidepressants
• Histamine H3 receptor antagonists

Market, By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Other pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa